FDA Working To Put A Price Tag On Ensuring Safety Of Personal Drug Imports
This article was originally published in The Pink Sheet Daily
Executive Summary
The number of personal imports is “overwhelming,” FDA’s McGinnis says. The National Association of Boards of Pharmacy reports it has collected approximately 100 reports of patient harm from imported products.
You may also be interested in...
FDA Import Program Would Need Funds To Inspect All U.S. Pharmacies, Agency Maintains
The pharmacy industry has told FDA all U.S. pharmacies will need to participate in a drug importation program to stay in business, so up to 55,000 pharmacies would have to be inspected, FDA's McGinnis says. "Draconian" penalties for non-complying drug manufacturers would ensure ample flow of drugs from Canada, he says.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states